Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
This collaboration turns kitting into a strategic advantage for sponsors and sites
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated